Cytodyn Inc (CYDY)

[Scooter McCabe]

So let's break this down:

We see the golden parachute clause altered to do two more things. Extend the amount of time of severance for the CEO. Not unusual to see severance packages improved for key personnel or CEO's when the company trends in the right direction.

Examples of CEO severance payouts, average is about 5.83 million.

The interesting change is the accelerated vesting. A big reason for having the ability to accelerate vesting is when a start up company is accquired and the person is deemed redundant. Forbes outlines what happens in a buyout and why acceleration of vesting is useful.

So in the event of a buyout Nader and Mulholland, the two most likely to be let go after a buyout, have had their contracts updated to reflect that.

So what does it mean? Well it suggests that buyout offers have moved from the realm of insulting to being entertained. Not surprising really, we have the drug. If the EIND results and blind study results match up, meaning 80% survival rate, we are the only credible treatment in town. With a pipeline into other diseases.

Would not surprise me if a big pharam company threw out 100 to 125 dollar a share offer. Gilead of all the pharmas has the most to lose if we walk onto the scene with a COVID/HIV drug that outshines what they have.

Gilead would likely try to buy us for the COVID and let it sit on the shelf as an HIV drug until their patents run out, and then submit it for HIV monotherapy. Getting around run at dominance in the HIV market.

Again, myth busted.